Navigation Links
Gates Foundation awards grant to tackle malaria
Date:2/16/2012

Can an innovative wallpaper-like liner help reduce the number of cases of malaria, and if so, will it be cost effective? Donald S. Shepard, a professor at the Schneider Institutes for Health Policy at the Heller School wants to know. And he has gotten the Bill and Melinda Gates Foundation to help. A grant, totaling nearly $500,000 over the next three years, will allow Shepard and collaborators to pursue their research in Kenya and Tanzania.

Shepard's four-person team includes Elizabeth Glaser, a doctoral student at Heller, Sareh Khoshi (M.S. '10), who will gather information in the US, and Aggrey Kihombo (Ph.D. '04), an expert in economic analysis in healthcare and faculty member at Mzumbe University in Tanzania. Kihombo is a former student of Shepard's.

"The research builds on a study that was launched a few years ago by the Centers for Disease Control in collaboration with the Kenya Medical Research Institute to measure the effectiveness of the wallpaper-like liner technology," says Shepard. "The material releases insecticides over several years. It has been found to be quite efficacious, and the economics of it are where we come in."

Recent data from results in Kenya found that the insecticide-treated wall liners cut malaria infections by 38 percent. To fully understand the benefits, Shepard and his team will be calculating additional outcomes, such as exploring the impact of childhood learning in the area school system. They will head to Africa in mid-February for two weeks.

According to the World Health Organization's Roll Back Malaria program, malaria kills 800,000 people in Africa each year91 percent of all malarial deaths worldwide.

Shepard estimates that the new technology could prevent as many as 300,000 deaths annually.

Shepard's four decades of research and teaching focus in the areas of international health, incentives to improve overall performance of the health system, and cost-effectiveness analysis. He specializes in HIV, cardiovascular disease, malaria and two other mosquito-borne illnesses--dengue and lymphatic filariasis.

Once the data are collected and analyzed, government agencies and members of donor communities will be among the most eager audiences as they seek to prevent those diseases.

"Malaria is one of the biggest killers in the world," says Shepard. "We've known how to treat it, but it's only been in recent years that prevention strategies have been implemented in a larger scale."

Currently, mosquito nets are the most widely implemented method to stave off malaria. The second strategy is indoor residual spraying. While progress has been made, Shepard hopes for more.

"This is one more very important tool that can overcome some of the limitations in existing technology and make a very substantial contribution," he says.


'/>"/>
Contact: Susan Chaityn Lebovits
lebovits@brandies.edu
781-736-4027
Brandeis University
Source:Eurekalert

Related medicine news :

1. Ghrelin mitigates liver fibrosis in animal models; regulates human fibrosis
2. Bill & Melinda Gates, Asian Parliamentary Group, Win 2010 United Nations Population Award
3. Long Island Press Investigates Big Tobacco's Lobby to Kill Indian Cigarette Trade
4. SC Johnson and Bill & Melinda Gates Foundation Unite to Combat Malaria
5. Food Safety Law Firm Investigates Major Outbreak of E. coli Linked To Lettuce
6. Georgia Tech awarded Gates Foundation grant for innovative global health research
7. Drug mitigates toxic effects of radiation in mice
8. AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access
9. Thesis investigates characteristics of society using sports activities as research tool
10. UI study investigates variability in mens recall of sexual cues
11. BUSM investigates cellular mechanisms leading to immune response in airway epithelium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... -centric training, today announced the launch of a new research study, The Business ... skills needed to execute that strategy, and the actual success of achieving individual ...
(Date:3/27/2017)... ... , ... According to the American Cancer Society , the average 15-year ... Once the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year ... this latter group, tune in to Lifestyle Magazine on April 9, 2017, ...
(Date:3/27/2017)... ... 2017 , ... Golden Triangle Emergency Center will be hosting ... to commemorate the two-year anniversary of the facility. The event will feature refreshments ... years while also familiarizing themselves with the facility. , In the two years ...
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: